JPS52105162A - Phthleic derivatives and preparation thereof - Google Patents

Phthleic derivatives and preparation thereof

Info

Publication number
JPS52105162A
JPS52105162A JP199777A JP199777A JPS52105162A JP S52105162 A JPS52105162 A JP S52105162A JP 199777 A JP199777 A JP 199777A JP 199777 A JP199777 A JP 199777A JP S52105162 A JPS52105162 A JP S52105162A
Authority
JP
Japan
Prior art keywords
phthleic
derivatives
preparation
phthleic derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP199777A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6135986B2 (enExample
Inventor
Peetaa Baagesa Kurausu
Sutausubaaru Tofuto Andaasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Kefalas AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS52105162(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas AS filed Critical Kefalas AS
Publication of JPS52105162A publication Critical patent/JPS52105162A/ja
Publication of JPS6135986B2 publication Critical patent/JPS6135986B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP199777A 1976-01-14 1977-01-13 Phthleic derivatives and preparation thereof Granted JPS52105162A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (2)

Publication Number Publication Date
JPS52105162A true JPS52105162A (en) 1977-09-03
JPS6135986B2 JPS6135986B2 (enExample) 1986-08-15

Family

ID=9722860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP199777A Granted JPS52105162A (en) 1976-01-14 1977-01-13 Phthleic derivatives and preparation thereof

Country Status (19)

Country Link
US (1) US4136193A (enExample)
JP (1) JPS52105162A (enExample)
AT (1) AT359488B (enExample)
AU (1) AU509445B2 (enExample)
BE (1) BE850401A (enExample)
CA (1) CA1094087A (enExample)
CH (3) CH626886A5 (enExample)
DE (1) DE2657013C2 (enExample)
DK (1) DK143275C (enExample)
ES (1) ES454980A1 (enExample)
FI (1) FI63754C (enExample)
FR (1) FR2338271A1 (enExample)
GB (1) GB1526331A (enExample)
IE (1) IE44055B1 (enExample)
NL (2) NL192451C (enExample)
NO (2) NO147243C (enExample)
NZ (1) NZ183001A (enExample)
SE (1) SE429551B (enExample)
ZA (1) ZA7757B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0236177A (ja) * 1988-06-14 1990-02-06 H Lundbeck As 新規鏡像体及びその単離法
JP2002531556A (ja) * 1998-12-08 2002-09-24 ハー・ルンドベック・アクチエゼルスカベット ベンゾフラン誘導体、その製造方法及びその使用方法
JP2005535322A (ja) * 2002-08-12 2005-11-24 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造に使用することができる中間体の分離方法
JP2006520351A (ja) * 2003-03-13 2006-09-07 エイドルケム テクノロジー エスピーエー シアノイソベンゾフランの製造方法
JP2007511477A (ja) * 2003-10-28 2007-05-10 エイドルケム テクノロジー エスピーエー シタロプラムの製造方法
JP2008105270A (ja) * 2006-10-25 2008-05-08 Shisuko:Kk 無湿乾燥用ホッパー装置
JP2011502981A (ja) * 2007-11-02 2011-01-27 ドン・ア・ファーム・カンパニー・リミテッド 新規な１，３−ジヒドロ−５−イソベンゾフランカルボニトリル誘導体およびそれを含む早漏症治療用医薬組成物

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
EP0759299B1 (en) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentiation of serotonin response
SK283309B6 (sk) * 1997-07-08 2003-05-02 H. Lundbeck A/S Spôsob výroby citalopramu a medziprodukty
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
DK1042310T3 (da) 1997-11-11 2002-12-02 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
ES2189502T3 (es) 1998-10-20 2003-07-01 Lundbeck & Co As H Metodo para la prevencion de citalopram.
KR20010081071A (ko) 1998-12-08 2001-08-25 피터슨 존 메이달 벤조푸란 유도체, 그것들의 제조 및 사용
IL143422A0 (en) 1998-12-23 2002-04-21 Lundbeck & Co As H Method for the preparation of 5-cyanophthalide
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
DK1173431T4 (da) * 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
DK1298124T3 (da) 1999-10-25 2007-07-09 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
CH692421A5 (de) * 1999-10-25 2002-06-14 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram.
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) * 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
JP2003519136A (ja) * 1999-12-28 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
DK1246813T3 (da) * 1999-12-30 2004-03-01 Lundbeck & Co As H Fremgangsmåde til fremstilling af Citalopram
AU3033700A (en) * 2000-01-14 2001-07-24 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
US6433196B1 (en) * 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
FR2805812A1 (fr) 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
AU2001242298A1 (en) 2000-03-13 2001-09-24 H Lunbeck A/S Method for the preparation of citalopram
KR20020080485A (ko) * 2000-03-13 2002-10-23 하. 룬트벡 아크티에 셀스카브 5-치환 1-(4-플루오로페닐)-1,3-디히드로이소벤조푸란의단계적 알킬화
ES2214400T3 (es) 2000-03-14 2004-09-16 H. Lundbeck A/S Metodo para la preparacion de citalopram.
DE10190485T1 (de) * 2000-03-16 2002-03-21 Lundbeck & Co As H Verfahren zur Herstellung von 5-Cyano-1-(4-fluorphenyl)-1,3-dihydroisobenzofuranen
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
AR032455A1 (es) * 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
WO2002004435A1 (en) * 2000-07-06 2002-01-17 H. Lundbeck A/S Method for the preparation of citalopram
CN100509791C (zh) * 2000-07-21 2009-07-08 H·隆德贝克有限公司 化合物及其作为甘氨酸转运抑制剂的用途
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
CA2354877C (en) * 2000-08-18 2006-05-02 H. Lundbeck A/S Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
CA2360303C (en) * 2000-12-22 2003-08-12 Marco Villa Process for the preparation of pure citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
SK284418B6 (sk) * 2000-12-28 2005-04-01 H. Lundbeck A/S Spôsob výroby citalopramu
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
CA2435925A1 (en) 2001-01-30 2002-08-08 Orion Corporation Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
EP1368330A1 (en) * 2001-02-22 2003-12-10 Natco Pharma Limited Process for the preparation of citalopram
GB0105627D0 (en) * 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
US20050085534A1 (en) * 2001-03-09 2005-04-21 Sujay Biwas Process for the preparation of citalopram
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (enExample) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
PT1522539E (pt) * 2001-07-31 2007-03-30 Lundbeck & Co As H Composição cristalina contendo escitalopram
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
IN192863B (enExample) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2387844B (en) * 2002-02-27 2005-05-11 Matrix Lab Ltd Separation of impurities from a crude mixture of citalopram
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
WO2003080558A1 (en) * 2002-03-27 2003-10-02 Bando Chemical Industries, Ltd. Novel 1,3,5-tris(arylamino)benzene
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
WO2004016602A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
MEP5808A (xx) * 2002-12-23 2010-02-10 Lundbeck & Co As H Ecitalopram bromhidrat i postupak za njegovo pripremanje
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
WO2004065375A1 (en) * 2003-01-17 2004-08-05 Natco Pharma Limited Processes for the preparation of escitalopram and its precursor
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7019153B2 (en) * 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
MXPA06003150A (es) * 2003-09-17 2006-08-31 Johnson & Johnson Compuestos heterociclicos fusionados.
EP1678122A4 (en) * 2003-10-28 2007-05-23 Wockhardt Ltd IMPROVED PROCESS FOR THE PREPARATION OF CITALOPRAM HYDROBROMIDE
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
EP1723133A1 (en) * 2004-02-16 2006-11-22 Jubilant Organosys Limited One pot synthesis of citalopram from 5-cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
EP1797060A2 (en) 2004-08-23 2007-06-20 Sun Pharmaceutical Industries Limited "process for preparation of citalopram and enantiomers"
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
WO2006116170A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
PE20061298A1 (es) 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
CA2605554A1 (en) 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
PE20061319A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
AU2006269231A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
PL1910346T3 (pl) * 2005-07-19 2019-09-30 Azevan Pharmaceuticals, Inc. Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009515840A (ja) * 2005-11-14 2009-04-16 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造方法
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
ATE534639T1 (de) 2007-04-23 2011-12-15 Synthon Bv Verfahren zur lösung von citalopram
AU2008252631B2 (en) * 2007-05-18 2012-12-20 Cipla Limited Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the S-isomer
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
RU2623209C9 (ru) 2010-07-01 2018-01-22 Азеван Фармасьютикалз, Инк. Способы лечения посттравматического стрессового расстройства
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
RS63296B1 (sr) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Metode lečenja depresije korišćenjem antagonista receptora oreksin-2
MX2020002762A (es) 2017-09-15 2020-09-17 Azevan Pharmaceuticals Inc Composiciones y métodos para tratar una lesión cerebral.
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (enExample) * 1965-03-18

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0236177A (ja) * 1988-06-14 1990-02-06 H Lundbeck As 新規鏡像体及びその単離法
JP2002531556A (ja) * 1998-12-08 2002-09-24 ハー・ルンドベック・アクチエゼルスカベット ベンゾフラン誘導体、その製造方法及びその使用方法
JP2005535322A (ja) * 2002-08-12 2005-11-24 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造に使用することができる中間体の分離方法
JP2011055842A (ja) * 2002-08-12 2011-03-24 H Lundbeck As エスシタロプラムの製造に使用することができる中間体の分離方法
JP2006520351A (ja) * 2003-03-13 2006-09-07 エイドルケム テクノロジー エスピーエー シアノイソベンゾフランの製造方法
JP2007511477A (ja) * 2003-10-28 2007-05-10 エイドルケム テクノロジー エスピーエー シタロプラムの製造方法
JP2008105270A (ja) * 2006-10-25 2008-05-08 Shisuko:Kk 無湿乾燥用ホッパー装置
JP2011502981A (ja) * 2007-11-02 2011-01-27 ドン・ア・ファーム・カンパニー・リミテッド 新規な１，３−ジヒドロ−５−イソベンゾフランカルボニトリル誘導体およびそれを含む早漏症治療用医薬組成物

Also Published As

Publication number Publication date
NO1996001I1 (no) 1996-01-05
SE429551B (sv) 1983-09-12
NO147243B (no) 1982-11-22
CH632259A5 (de) 1982-09-30
DE2657013A1 (de) 1977-07-28
NO770109L (no) 1977-07-15
DK13177A (da) 1977-07-15
AU509445B2 (en) 1980-05-15
IE44055B1 (en) 1981-07-29
FR2338271B1 (enExample) 1982-11-05
SE7614201L (sv) 1977-07-15
CA1094087A (en) 1981-01-20
AU2107377A (en) 1978-07-13
NL192451C (nl) 1997-08-04
CH626886A5 (enExample) 1981-12-15
ATA947276A (de) 1980-04-15
DK143275B (da) 1981-08-03
ES454980A1 (es) 1978-04-01
NL7700244A (nl) 1977-07-18
BE850401A (fr) 1977-07-14
CH632258A5 (de) 1982-09-30
JPS6135986B2 (enExample) 1986-08-15
NO147243C (no) 1983-03-02
NZ183001A (en) 1978-06-02
GB1526331A (en) 1978-09-27
US4136193A (en) 1979-01-23
DE2657013C2 (de) 1985-11-14
FI770073A7 (enExample) 1977-07-15
NL970031I2 (nl) 1997-10-01
AT359488B (de) 1980-11-10
IE44055L (en) 1977-07-14
FR2338271A1 (fr) 1977-08-12
FI63754C (fi) 1983-08-10
ZA7757B (en) 1977-11-30
DK143275C (da) 1982-01-18
FI63754B (fi) 1983-04-29
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01

Similar Documents

Publication Publication Date Title
JPS52105162A (en) Phthleic derivatives and preparation thereof
JPS52105131A (en) Substituted phenylamidines and preparation thereof
IL59567A0 (en) Oxiranylmethyltetrahydropyran derivative and its preparation
IL53504A (en) Polyfluoroallyloxy compounds and their preparation
IL60155A0 (en) Substituted phenoxybenzylalcohols and their preparation
JPS5379844A (en) Cyclopentanee11amine and like * and its preparation
HK60184A (en) 4-hydroxyphenylalkanolamine derivatives and preparation thereof
JPS5379841A (en) Aminoosugar derivative * its preparation and use
JPS52111552A (en) 44androstenee33one and preparation thereof
JPS5289669A (en) Thiazolidine derivatives and preparation thereof
JPS5312861A (en) Benzimdazole derivative and its preparation
JPS52148061A (en) 66carboxymethyl thiocortisol and derivatives thereof
JPS5325565A (en) Novel aryltrifluoroethylamine and its preparation
GB1519747A (en) 2 - arylpiperazine derivatives and the preparation thereo
ZA776647B (en) New piperidinopropyl derivatives and the preparation thereof
JPS52131534A (en) Aralkylarylamine and preparation thereof
JPS5291859A (en) 22furanones and preparation thereof
IL52668A (en) 7 -amino-1-oxa-1-dethiacephalosporins and their preparation
JPS5315368A (en) Novel 22phenyllindole derivative and preparation thereof
JPS5346977A (en) 55secondary alkylidenehydantoin and its preparation
JPS52100480A (en) Substituted ppaminophenyllasstriazinedione and its preparation
JPS52116462A (en) 22oxoopyrrolidine derivative and preparation thereof
JPS5297953A (en) Tetrahydronaphthaline triol derivatives and preparation thereof
JPS5291863A (en) Novel 22nitroimidazole derivatives and preparation thereof
JPS52118459A (en) 22furanone derivative and preparation thereof